LX 9851
Alternative Names: LX-9851Latest Information Update: 17 May 2024
At a glance
- Originator Lexicon Pharmaceuticals
- Class Obesity therapies; Small molecules
- Mechanism of Action ACSL5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 04 May 2024 Lexicon Pharmaceuticals announces intention to file IND for Obesity in 2025
- 04 May 2024 Lexicon Pharmaceuticals plans to initiate IND-enabling studies for Obesity in 2024
- 29 Apr 2024 LX 9851 is available for licensing as of 29 Apr 2024. https://www.lexpharma.com/pipeline (Lexicon Pharmaceuticals website; April 2024)